SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?


To: eico20 who wrote (1314)6/17/2015 8:27:57 PM
From: mokelumne river  Respond to of 2026
 
And I am hoping that RayVa Phase 3 is much cheaper.



To: eico20 who wrote (1314)6/17/2015 8:49:58 PM
From: phoenix_rising  Read Replies (1) | Respond to of 2026
 
These numbers are what RPRX spent over 2012-2014 on R&D , so should give a rough idea of P3 costs

31/12/2014 31/12/2013 31/12/2012
Period Ending
Total Revenue- - -
Cost of Revenue- - -
Gross Profit- - -
Operating Expenses
Research Development27,107 23,657 14,120